化合物 T11813 T11813

Product Introduction
Bioactivity


英文名: Laflunimus

描述: Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor. Laflunimus is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH).

体外活性: Laflunimus inhibits LPS-induced kappa light-chain cell surface expression on 70Z/3 cells, a property also reversed by uridine. Laflunimus is more potent than A77 1726 as an inhibitor of PGHS in guinea pig polymorphonuclear leukocytes (IC50= 415 and 4400 nM, respectively) and on isolated ovine PGHS-1 (IC50=64 and 742 μM) and PGHS-2 (IC50=100 and 2766 μM).Ig secretion from mouse splenocytes was induced by lipopolysaccharide (LPS) for 5 days.?Laflunimus inhibited the secretion of IgM and IgG with IC50 values of 2.5 and 2 μM , respectively.?Adding Uridine (50 μ M) increased these values to 70 and 60 μ M, respectively.

体内活性: HR325?inhibits the secondary anti-sheep red blood cell (SRBC) antibody response with ID50 values of 38 mg/kg.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: HR-325 | HR 325 | Laflunimus

化合物 T11813 T11813信息由TargetMol中国为您提供，如您想了解更多关于化合物 T11813 T11813报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途